← Evidence library

BIB_325

Schadendorf D, Long GV et al. COMBI-AD ctDNA biomarker analysis: BRAFV600 ctDNA as prognostic marker in resected stage III melanoma receiving adjuvant dabrafenib + trametinib. Lancet Oncol 2025. ctDNA-MRD increasingly clinically actionable in BRAF-mutated Stage III. [Tasks: 06, 15, 17, 19b] Tier: 1 (Lancet Oncol) Grade: B Retrieved: 2026-05-15

Evidence grade

B

Tier

1 (Lancet Oncol)

Cited by tasks

06, 15, 17, 19b

Identifiers

—

Full extracted findings & patient-implication analysis: bibliography/BIB_325/findings.md (research corpus). This page is a short context summary — not individualised medical advice.